Payment overview · 2025
General Payments
$1,288.53
33 reported records · 10 companies
Healthcare provider profile · identity verified
David E Brister, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · AMARILLO, TX · NPI 1568409589
Verified facts
What the public records show
CMS Open Payments records show David E Brister, M.D. received $1,288.53 in general payments during 2025 across 33 reported records.
Novo Nordisk Inc accounted for 24.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $319.15 | 24.8% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $278.12 | 21.6% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $188.81 | 14.7% | 6 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $143.58 | 11.1% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $124.72 | 9.7% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $87.64 | 6.8% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $74.67 | 5.8% | 4 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $37.33 | 2.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.67 | 1.4% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15.84 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,288.53 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $198.00 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $177.49 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $143.58 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $124.72 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $121.15 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $100.63 | 5 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $87.64 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $74.67 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $73.00 | 4 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $37.33 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $36.62 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $36.62 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $27.19 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $15.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 127 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
127 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 585 | 123 |
| Amlodipine Besylate | Amlodipine Besylate | 512 | 123 |
| Atorvastatin Calcium | Atorvastatin Calcium | 400 | 90 |
| Pantoprazole Sodium | Pantoprazole Sodium | 271 | 59 |
| Tramadol Hcl | Tramadol Hcl | 261 | 83 |
| Allopurinol | Allopurinol | 244 | 52 |
| Pioglitazone Hcl | Pioglitazone Hcl | 232 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 229 | 51 |
| Gabapentin | Gabapentin | 228 | 46 |
| Metformin Hcl | Metformin Hcl | 227 | 50 |
| Pregabalin | Pregabalin | 198 | 41 |
| Losartan Potassium | Losartan Potassium | 197 | 50 |
| Celecoxib | Celecoxib | 195 | 52 |
| Azelastine Hcl | Azelastine Hcl | 163 | 118 |
| Metoprolol Succinate | Metoprolol Succinate | 159 | 38 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 156 | 33 |
| Omeprazole | Omeprazole | 154 | 38 |
| Meloxicam | Meloxicam | 150 | 29 |
| Lisinopril | Lisinopril | 147 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 146 | 43 |
| Bupropion Xl | Bupropion Hcl | 136 | 28 |
| Simvastatin | Simvastatin | 136 | 33 |
| Ibandronate Sodium | Ibandronate Sodium | 133 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 131 | 27 |
| Potassium Chloride | Potassium Chloride | 130 | 32 |
| Jardiance | Empagliflozin | 127 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 127 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 126 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 126 | 29 |
| Furosemide | Furosemide | 121 | 26 |
| Raloxifene Hcl | Raloxifene Hcl | 118 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 113 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 111 | 26 |
| Ramipril | Ramipril | 105 | 19 |
| Methylprednisolone | Methylprednisolone | 100 | 77 |
| Amoxicillin | Amoxicillin | 99 | 82 |
| Tizanidine Hcl | Tizanidine Hcl | 98 | 40 |
| Cefdinir | Cefdinir | 93 | 73 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 92 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 89 | 21 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 79 | 19 |
| Torsemide | Torsemide | 79 | 25 |
| Trazodone Hcl | Trazodone Hcl | 75 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 74 | 33 |
| Alprazolam | Alprazolam | 73 | 15 |
| Famotidine | Famotidine | 72 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 70 | 11 |
| Methocarbamol | Methocarbamol | 70 | 20 |
| Lorazepam | Lorazepam | 67 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 66 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 66 | 16 |
| Montelukast Sodium | Montelukast Sodium | 64 | 16 |
| Aripiprazole | Aripiprazole | 63 | 18 |
| Clonidine Hcl | Clonidine Hcl | 60 | 13 |
| Entresto | Sacubitril/Valsartan | 59 | 11 |
| Sertraline Hcl | Sertraline Hcl | 59 | 14 |
| Carvedilol | Carvedilol | 56 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 16 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 49 | 11 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 48 | 33 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 46 | suppressed |
| Irbesartan | Irbesartan | 44 | 11 |
| Lovastatin | Lovastatin | 44 | 13 |
| Eszopiclone | Eszopiclone | 43 | 12 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 43 | suppressed |
| Valsartan | Valsartan | 43 | 14 |
| Donepezil Hcl | Donepezil Hcl | 42 | 13 |
| Mirtazapine | Mirtazapine | 42 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | suppressed |
| Prednisone | Prednisone | 42 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 41 | suppressed |
| Eliquis | Apixaban | 40 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 40 | suppressed |
| Finasteride | Finasteride | 38 | suppressed |
| Ozempic | Semaglutide | 37 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 36 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 27 |
| Clindamycin Hcl | Clindamycin Hcl | 35 | 22 |
| Propranolol Hcl Er | Propranolol Hcl | 35 | suppressed |
| Glimepiride | Glimepiride | 34 | suppressed |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Zaleplon | Zaleplon | 34 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | suppressed |
| Spironolactone | Spironolactone | 33 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 32 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 31 | suppressed |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 21 |
| Paxlovid | Nirmatrelvir/Ritonavir | 30 | 30 |
| Synthroid | Levothyroxine Sodium | 30 | 11 |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Indapamide | Indapamide | 28 | suppressed |
| Hydrocortisone | Hydrocortisone | 27 | suppressed |
| Nystatin | Nystatin | 27 | 16 |
| Azithromycin | Azithromycin | 26 | 23 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 26 | 22 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 21 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Colchicine | Colchicine | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Temazepam | Temazepam | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Metronidazole | Metronidazole | 21 | 16 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 13 |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Zafirlukast | Zafirlukast | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 14 | suppressed |
| Klor-Con 10 | Potassium Chloride | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Prograf | Tacrolimus | 13 | suppressed |
| Tacrolimus | Tacrolimus | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Acarbose | Acarbose | 12 | suppressed |
| Dipyridamole | Dipyridamole | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 11 |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 12 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 12 | suppressed |
| Aripiprazole Odt | Aripiprazole | 11 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 11 | 11 |
| Neomycin-Bacitracin-Polymyxin | Neomycin/Bacitracin/Polymyxinb | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,288.53 · 33 records | Novo Nordisk Inc | AIRSUPRA, Auvelity, BREZTRI, ELIQUIS, INSPIRE, JARDIANCE, KISUNLA, Leqembi, MOUNJARO, Ozempic, REXULTI, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, Wegovy, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error